Results 91 to 100 of about 1,425,061 (397)

Body weight loss after surgery affects the continuity of adjuvant chemotherapy for pancreatic cancer

BMC Cancer, 2019
Background Postoperative chemotherapy is beneficial for many pancreatic cancer patients. However, some patients require dose reduction or the discontinuation of adjuvant chemotherapy because of adverse treatment-related effects.
Yoshifumi Morita, Takanori Sakaguchi, Ryo Kitajima, Satoru Furuhashi, Ryota Kiuchi, Makoto Takeda, Takanori Hiraide, Yasushi Shibasaki, Hirotoshi Kikuchi, Hiroyuki Konno, Hiroya Takeuchi   +10 more
doaj   +1 more source

Association Between Adjuvant Chemotherapy and Overall Survival in Patients With Rectal Cancer and Pathological Complete Response After Neoadjuvant Chemotherapy and Resection

JAMA Oncology, 2018
Importance Although American guidelines recommend use of adjuvant chemotherapy in patients with locally advanced rectal cancer, individuals who achieve a pathological complete response (pCR) following neoadjuvant chemoradiotherapy are less likely to ...
F. Dossa, S. Acuna, A. Rickles, M. Berho, S. Wexner, F. Quereshy, N. Baxter, S. Chadi   +7 more
semanticscholar   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0–1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database

BMC Cancer, 2020
Background The benefit of adjuvant chemotherapy in invasive lobular carcinoma (ILC) is still unclear. The objective of the current study was to elucidate the effectiveness of adjuvant chemotherapy in hormone receptor (HR)-positive, human epidermal growth
Guangfu Hu, Guangxia Hu, Chengjiao Zhang, Xiaoyan Lin, Ming Shan, Yanmin Yu, Yongwei Lu, Ruijie Niu, Hui Ye, Cheng Wang, Cheng Xu   +10 more
doaj   +1 more source

First-line therapy in HER2 positive metastatic breast cancer. Is the mosaic fully completed or are we missing additional pieces? [PDF]

, 2016
The discovery of human epidermal growth factor receptor 2 (HER2) and its role in the biology of breast cancer and the subsequent development of HER2-targeted therapies, have dramatically improved clinical outcomes for women with early-stage and advanced ...
Cognetti F., Fabi A., Malaguti P., Vari S.   +3 more
core   +2 more sources

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Intraperitoneal chemotherapy for peritoneal metastases : an expert opinion

, 2020
Introduction: The rationale for intraperitoneal (IP) drug delivery for patients with peritoneal metastases (PM) is based on the pharmacokinetic advantage resulting from the peritoneal-plasma barrier, and on the potential to adequately treat small, poorly
Braet, Helena, Ceelen, Wim, Remaut, Katrien, Van Ramshorst, Gabrielle, Willaert, Wouter   +4 more
core   +1 more source

Total Mesometrial Resection With (Neo)Adjuvant Chemotherapy in Locally Advanced Cervical Cancer: A Tumor Response Score [PDF]

, 2021
Matthias Kiesel, Stephanie Sauer, Sanja Löb, Saskia Herbert, Achim Wöckel, Christine Wulff   +5 more
openalex   +1 more source

Dietary nitrate and nitrite protect against doxorubicin‐induced cardiac fibrosis and oxidative protein damage in tumor‐bearing mice

FEBS Open Bio, EarlyView.
Chemotherapies such as doxorubicin can have toxic effects on healthy cardiovascular/heart tissue. Following up on a doxorubicin toxicity study in mice without tumors where nitrate water was cardioprotective (lessened toxicity), this study with tumor‐bearing mice undergoing doxorubicin treatment showed no negative effect of nitrate and nitrite on drug ...
Rama D. Yammani, Xiaofei Chen, Nildris Cruz‐Diaz, Xuewei Zhu, Swati Basu, Daniel B. Kim‐Shapiro, David R. Soto‐Pantoja, Leslie B. Poole   +7 more
wiley   +1 more source

Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines [PDF]

, 2013
The potential clinical utility of genetic markers associated with response to fluoropyrimidine treatment in colorectal cancer patients remains controversial despite extensive study.
A Fariña-Sarasqueta, A Loganayagam, A Ruzzo, A Ruzzo, A Yawata, A Zaniboni, Andreas-Claudius Hoffmann, Ann Barrett, B Glimelius, BA Jennings, Barbara A. Jennings, C Fernandez-Rozadilla, C Zhang, CE de Bock, CF Thorn, D Caronia, Daniel Epurescu, DB Longley, E Hitre, E Van Cutsem, G Willis, Gavin S. Chu, Gavin Willis, H Gellekink, H Taflin, I Weisberg, J Cassidy, Jane Skinner, K Derwinger, K Kawakami, K Kawakami, L Peter, L Sharp, M Boisdron-Celle, M Gusella, M Scartozzi, M Schwab, M Vignoli, ME Fernández-Contreras, Melanie Keane, MJ Deenen, MS Braun, MV Mandola, MV Mandola, MV Mandola, N Horie, P Frosst, R Pullmann Jr., RA Goodwin, Richard Turner, S Afzal, S Afzal, S Kaneda, T André, TV Perneger, V Sulzyc-Bielicka, W Ichikawa, W Scheithauer, WG Johnson, Yoon K. Loke   +59 more
core   +3 more sources